Filing Flows › 8-K events › PAVmed
PAVmed: entry into a material definitive agreement
Form 8-K filed Oct 22, 2026 · items 1.01, 3.03
What the filing says
Effective as of October 21, 2026, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors (collectively, the “ Investors ”), which agreements provided for the sale to th
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 3.03: +0.1% next session across 1,456. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
PAVmed at a glance
PAVmed, Q2 2026: revenue $33K (+450% year over year). The chart follows the revenue to costs, profit and cash.
PAVmed: every quarter, Q/Q and Y/Y, holders and guidance →
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.